4.7 Article

Lack of Association Between Heart Failure and Incident Cancer

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 71, 期 14, 页码 1501-1510

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.01.069

关键词

heart failure; incident cancer; malignancy; tumor

资金

  1. National Heart, Lung, and Blood Institute
  2. National Cancer Institute [CA-34944, CA-40360, CA-097193]
  3. National Heart, Lung, and Blood Institute [HL-26490, HL-34595]
  4. Merck
  5. Amarin Pharman
  6. American Egg Board
  7. Amarin
  8. Amgen
  9. AstraZeneca
  10. Bristol-Myers Squibb
  11. Chiesi
  12. Eisai
  13. Ethicon
  14. Forest Laboratories
  15. Ironwood
  16. Ischemix
  17. Lilly
  18. Medtronic
  19. Pfizer
  20. Roche
  21. Sanofi
  22. The Medicines Company

向作者/读者索取更多资源

BACKGROUND Several recent studies have suggested an increased cancer risk among patients with heart failure (HF). However, these studies are constrained by limited size and follow-up, lack of comprehensive data on other health attributes, and adjudicated cancer outcomes. OBJECTIVES This study sought to determine whether HF is associated with cancer incidence and cancer-specific mortality. METHODS The study assembled a cohort from the Physicians' Health Studies I and II, 2 randomized controlled trials of aspirin and vitamin supplements conducted from 1982 to 1995 and from 1997 to 2011, respectively, that included annual health evaluations and determination of cancer and HF diagnoses. In the primary analysis, the study excluded participants with cancer or HF at baseline and performed multivariable-adjusted Cox models to determine the relationship between HF and cancer, modeling HF as a time-varying exposure. In a complementary analysis, the study used the landmark method and identified cancer-free participants at 70 years of age, distinguishing between those with and without HF, and likewise performed Cox regression. Sensitivity analyses were performed at 65, 75, and 80 years of age. RESULTS Among 28,341 Physicians' Health Study participants, 1,420 developed HF. A total of 7,363 cancers developed during a median follow-up time of 19.9 years (25th to 75th percentile: 11.0 to 26.8 years). HF was not associated with cancer incidence in crude (hazard ratio: 0.92; 95% confidence interval: 0.80 to 1.08) or multivariable-adjusted analysis (hazard ratio: 1.05; 95% confidence interval: 0.86 to 1.29). No association was found between HF and site-specific cancer incidence or cancer-specific mortality after multivariable adjustment. Results were similar when using the landmark method at all landmark ages. CONCLUSIONS HF is not associated with an increased risk of cancer among male physicians. Published by Elsevier on behalf of the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据